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ABSTRACT The pathogenetic mechanism of the mito-
chondrial tRNAuLuuR gene mutation responsible for the MELAS(mitochondrial myopathy, encephalopathy, lactic acidosis, and
stroke-like episodes) syndrome was investigated in transform-
ants obtained by tanser of mitochondria from three geneti-
cally unrelated MELAS patients into human mitochondrial
DNA (mtDNA)-less (O9) cells. Marked defects in mitochondrial
protein synthesis and respiratory activity were observed in
transformants containing virtually pure mutant mtDNA, as
compared to the parent of the p0 cells (the 143B cell line) or to
transformants containing exclusively wild-type mtDNA, de-
rived from one of the patients or a maternally related asymp-
tomatic individual. A strking protective effect against the
mutation was exerted in the transformants by levels of residual
wild-type mtDNA above 6%. The MELAS mutation occurs
within the mtDNA binding site for a protein factor (mTERF)
that promotes termination of transcription at the 16S
rRNA/tRNAbN gene boundary. A marked decrease in affin-
ity of purified mTERF for the mutant target sequence was
observed in in vitro assays. By contrast, RNA transfer hybrid-
ization experiments failed to show any sgiicant change in the
steady-state amounts of the two rRNA species, encoded up-
stream of the termination site, and of the mRNAs encoded
downstream, in the transformants carrying the MELAS mu-
tation.
In the present work, the approach of mitochondria-mediated
transformation utilizing human mtDNA-less (p0) cells as
recipients (1, 2) has been used to investigate the pathogenetic
mechanism of the mtDNA mutation responsible for the
MELAS syndrome (3-5). The mutation occurs in the binding
site for the transcription termination factor (mTERF) (6)
within the tRNA'uIJR gene. The results indicate that repop-
ulation of p0 cells with mitochondria carrying the MELAS
mutation in their DNA produces transformants exhibiting
severe protein-synthesis and respiration defects, but no sig-
nificant change in the steady-state levels of the heavy (H)-
strand-encoded rRNAs and mRNAs (7). Therefore, although
the MELAS mutation strongly decreases the affinity in vitro
of mTERF for the target sequence, its pathogenetic mecha-
nism does not involve a change in the absolute and relative
amounts of the RNA species encoded in the two mtDNA
H-strand transcription units (7).
MATERIALS AND METHODS
Cell Lines, Myoblast Cultures, and Mitochondria-Mediated
Transformation. Conditions of growth of the thymidine ki-
nase-deficient 143B human osteosarcoma cell line (ATCC
CRL 8303) and ofthe p0206 cell line, a mtDNA-less derivative
of 143B, were as described (1). Mass myoblast cultures from
the first patient ("43") and his asymptomatic maternally-
related aunt ("94"), from the second patient ("2S"), and
from the third patient ("59") were established by published
procedures (8-10). Mitochondria-mediated transformation of
p0 cells was carried out by fusion with enucleated myoblasts
(2).
Extraction, Electrophoresis, and Blot Hybridization Analy-
sis of RNA. Extraction and oligo(dT)-cellulose chromatogra-
phy of nucleic acids from the mitochondrial fraction were
carried out essentially as described (11). Electrophoresis of
nucleic acids in a 1.4% agarose/10 mM CH3HgOH gel,
electroblotting, and hybridization with a 32P-labeled HeLa
cell mtDNA probe were performed as previously detailed
(12).
For tRNA blot hybridization analysis, samples of nucleic
acids from the mitochondrial fraction were electrophoresed
as described (13) and electroblotted onto a Nytran 0.2-gm
membrane (Schleicher & Schuell). The tRNAs were then
crosslinked to the membrane by irradiation with a short-
wavelength transilluminator. The blots were hybridized with
32P-labeled probes containing the tRNAbuR gene (clone A2,
carrying the mtDNA fragment spanning positions 8287-8591,
in pGEM-1) or the tRNAIYI gene (clone MTC2, carrying the
fiagment spanning positions 2953-4121, in pUC19) at 520C
overnight, as previously described (12), except for the omis-
sion of formamide and dextran sulfate.
Southern Blot and PCR Analysis of DNA. Southern blot
analysis of mtDNA in the total nucleic acids of the mito-
chondrial fraction, after digestion with EcoRV endonuclease,
was carried out by standard procedures, with 32P-labeled
HeLa cell mtDNA as a probe. The presence and proportion
of mutated mtDNA in total cell DNA, prepared by using an
Applied Biosystems 340A DNA extractor or by lysis of cells
with Tween 20 and proteinase K digestion, were determined
by testing for the presence of the Apa I site created by the
MELAS mutation (3-5) at position 3243 (14) in a PCR-
amplified DNA fragment. The amplified fragment was di-
gested with Apa I in the presence of pBluescript KS(+)
(Stratagene) DNA linearized with Xmn I, as an internal
marker for completion of digestion, and analyzed by agarose
gel electrophoresis. The proportion of digested and undi-
gested molecules was determined by laser densitometry after
ethidium bromide staining and was corrected for the resis-
tance to digestion of heteroduplexes of wild-type and mutant
mtDNA on the basis of a mixed-template standard curve
(M.Y., A.C., A.M., and G.A., unpublished data).
Gel Retardation Assays. Equal samples of affinity column-
purified mTERF (6) were mixed with 2.5 ng of a double-
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stranded oligonucleotide containing the wild-type sequences
protected by mTERF (6) or of the homologous double-
stranded oligonucleotide carrying the MELAS mutation at
position 3243 (labeled with ['t_32P]ATP and polynucleotide
kinase), and the mixtures were incubated on ice. After 45 min
(time sufficient to give equilibrium binding) or longer, a
200-fold molar excess of the corresponding unlabeled probe
was added to all samples but two controls, and the samples
were incubated further and, finally, run in a nondenaturing
polyacrylamide gel (15).
Analysis of Mitochondrial Protein Synthesis and Measure-
ment of 02 Consumption. Labeling with [35S]methionine and
electrophoresis of the mitochondrial translation products and
02 consumption measurements were carried out as described
(2).
RESULTS
Mitochondria Transfer from Three MELAS Patients and an
Asymptomatic Relative's Myoblasts to p0 Cells. The first
patient ("43") was a 19-year-old Caucasian man who exhib-
ited the MELAS mutation in heteroplasmic form in the
mtDNA from muscle and blood (A.M., L. Bartolomei, R.
Carrozzo, M. L. Mostacciuolo, C. Carbonin, V. Toso, E.
Ciafaloni, S. Di Mauro, and C. Angelini, unpublished data).
The second patient ("2S") was an isolated 34-year-old
Caucasian man who displayed a characteristic MELAS syn-
drome, as well as chronic progressive external ophthalmople-
gia, sensorineural deafness, and pigmentary retinopathy and
exhibited the MELAS mutation in heteroplasmic form in the
muscle, peripheral blood, and urinary epithelial cells (16, 17).
The third patient ("59") was an isolated 28-year-old Jap-
anese man who displayed typical MELAS symptoms and
exhibited the MELAS mutation in heteroplasmic form in the
muscle.
mtDNA analysis of muscle from patient 43 and his aunt
("94") showed a mutant mtDNA content of 93% and 75%,
respectively (Fig. la). The patient 43-derived myoblast cul-
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FIG. 1. Detection of the MELAS mutation in the muscle (Mu.)
biopsy specimens, myoblast (Myo.) cultures, and mitochondrial
transformants from patient 43 and his aunt ("94") (a) and from
patients 2S and 59 (b). Indicated are the expected sizes of the PCR
product (330 base pairs) and of the fragments produced by Apa I
digestion of the MELAS mutation-containing PCR product (214 and
116 base pairs). For the quantitation, see Materials and Methods. P,
patient; R, relative; M, Hae III-digested pBluescript KS(+) DNA;
lin.KS, Xmn I-linearized pBluescript KS(+) DNA.
ture contained predominantly (92%) mutant mtDNA, while
the relative-derived culture contained 55% mutant mtDNA.
After fusion of enucleated myoblasts from the two sources
with p0206 cells, 3 and 10 colonies, respectively, of presump-
tive mitochondrial transformants were isolated in selective
medium (1).
Three to 6 weeks after transformation, the three patient
43-derived transformants (43A, 43B, and 43C) contained
almost exclusively (97-99%) mutant mtDNA (Fig. la). By
contrast, five of the six relative-derived transformants cho-
sen for analysis (94B to 94E and 941) exhibited pure or
virtually pure wild-type mtDNA. One relative-derived trans-
formant (94A) contained 92% mutated mtDNA.
Among 14 transformant clones obtained from patient 2S, 10
clones were found, 5 weeks after transformation, to be
apparently homoplasmic for wild-type mtDNA, and 4 con-
tained strongly predominant mutant mtDNA. Five of the
above clones were chosen for further study (Fig. lb). Four
transformant clones were obtained from patient 59, and,
when tested 8 weeks after transformation, they all showed
strongly predominant mutant mtDNA (Fig. lb).
Mitochondrial Protein Synthesis in Transformants. Four to
6 weeks after transformation, transformants 94A, 94B, and
94C exhibited a pattern and rate of labeling with [35S]methio-
nine of the mitochondrial translation products comparable to
those of 143B cells (Fig. 2a). This result was unexpected for
transformant 94A, which contained 92% mutated mtDNA
(Fig. 1). By contrast, the overall rate of labeling of the
mitochondrial translation products in transformants 43A,
43B, and 43C appeared to be significantly decreased (64-77%
and 67-78%, respectively) when compared with the labeling
of 94B and 143B cells. Moreover, the labeling of cytochrome
c oxidase subunits COII and COIII and of ND2 was more
severely affected than that of the other polypeptides. No
relationship was detected between the extent of decrease in
labeling of the individual polypeptides and their absolute
content in UUR-encoded leucine residues (data not shown).
The pattern of mitochondrial protein synthesis in the
transformants derived from patient 2S, 8 weeks after trans-
formation, also showed a clear decrease (50-70%) in the
overall rate of labeling in the transformants with strongly
predominant mutant mtDNA (2SC and 2SD) (Fig. 3a), as
compared to 2SA, 2SB, and 2SE. A repeat of genotype
analysis at this time revealed, unexpectedly, in 2SE an
increase in proportion of mutant mtDNA from apparently
none to 50% (Fig. lb). In 2SC and 2SD, the COII, COIII, and
ND2 polypeptides were more severely affected in their
labeling than the other polypeptides. The four transformants
with strongly predominant mutant mtDNA derived from
patient 59 showed, 8 weeks after transformation, a marked
overall decrease in the rate ofprotein labeling relative to 143B
cells (85-95%), the reduction in labeling being again more
pronounced for COII, COIII, and ND2 (Fig. 3b).
Respiration Capacity of Transformants. Eight to 10 weeks
after transformation, transformants 43A, 43B, and 43C ex-
hibited a marked decrease in 02 consumption as compared to
143B cells (Fig. 2b). By contrast, the five analyzed trans-
formants derived from the unaffected relative, including,
most remarkably, the 94A transformant, which had 92%
mutant mtDNA, all exhibited an 02 consumption rate com-
parable to that of 143B cells.
An analysis of the 43B and 94B mtDNA at the time of 02
consumption revealed that, while the 43B genotype was
unchanged, in 94B there had been, unexpectedly, a dramatic
increase in the proportion of mutant mtDNA, from <10%1, as
measured 5 weeks earlier, to 89%. This phenomenon has
been investigated further (M.Y., A.C., A.M., and G.A.,
unpublished work). In contrast to the change in genotype, 02
consumption in 94B still was in the normal range, therefore
reproducing the situation observed for 94A.
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FIG. 2. Mitochondrial transformants derived from patient 43
myoblasts are defective in mitochondrial protein synthesis and
respiratory capacity, but those derived from the myoblasts ofasymp-
tomatic relative 94 have a normal phenotype. (a) Mitochondrial
translation products (30-min [35S]methionine pulse; equal protein
samples after correction for decay, except the 94A sample, which
contained 50o more protein) run in an SDS/polyacrylamide gradient
gel. COI, COI, and COIII, subunits I, II, and III of cytochrome c
oxidase; ND1, ND2, ND3, ND4, ND4L, ND5, and ND6, subunits 1,
2, 3, 4, 4L, 5, and 6 of the respiratory-chain NADH dehydrogenase;
A6 and A8, subunits 6 and 8 of the H'-ATPase; CYTb, apocy-
tochrome b. (b) Rate of 02 consumption (error bars represent 2 SE)
in transformants 43A, 43B, 43C, 94A, 94B, 94D, 94E, and 941 and in
143B cells.
The transformant with equivalent proportions of mutant
and wild-type mtDNA and the two transformants homoplas-
mic for wild-type mtDNA derived from patient 2S showed, 8
weeks after transformation, an 02 consumption comparable
to that of 143B cells (Fig. 3a). By contrast, the two patient
2S-derived (Fig. 3a) and four patient 59-derived (Fig. 3b)
transformants with strongly predominant mutant mtDNA
showed a marked decrease in 02 consumption.
A Small Minority of Wild-Type mtDNA Protects the Trans-
formants Against the Effects of the MELAS Mutation. A
diagram illustrating the relationship between proportion of
mtDNA carrying the MELAS mutation and degree of respi-
ratory activity in various mitochondrial transformants ana-
lyzed in the present work is shown in Fig. 4. There is a sharp
threshold, around 6%, in wild-type mtDNA proportion,
02 use 4.7 4.7 0.86 1.3 5.3 0.81 0.85 0.63 0.88
FIG. 3. Mitochondrial protein synthesis pattern and respiratory
capacity of transformants derived from patients 2S (a) and 59 (b).
Shown are the labeling patterns after a 30-min [35S]methionine pulse
(25 ,gg of protein per sample) in several transformants and in 143B
cells. Symbols are as in Fig. 2. The 02 consumption data for the
transformants are expressed in fmol/min per cell.
above which this DNA protects against the phenotypic
effects of the mutation, with full protection by -10% wild-
type mtDNA.
The MELAS Mutation Strongly Reduces the Affinity of
mTERF for the Termination Site. To test whether the MELAS
mutation affected the affinity of mTERF for the termination
site, dissociation rates were measured in gel retardation
assays (15). The half-life of the complex involving the mu-
tated sequence was between 5 and 6 min, whereas that of the
complex involving the wild-type sequence was between 40
and 50 min (Fig. 5).
0
5F
4
Co
CO E4-
3F
I
0
* 94A,B,D,E,I
o 43A,BC
* 2SA,B,C,D,E
a 59A,B,C,D
2
i
0
10 40 60 80 100
% WT mtDNA
FIG. 4. A small minority of wild-type (WT) mtDNA can protect
the mitochondrial transformants against the respiratory defect
caused by the MELAS mutation.
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FIG. 5. Kinetics of dissociation of complexes ofmTERF with the
wild-type DNA probe or the MELAS mutation-carrying probe. (a)
Gel retardation assays. The slower band in each lane represents the
mTERF-DNA complex, the faster band, uncomplexed probe. The
times of incubation of the samples (after the initial 45 min) in the
absence (controls) or presence of competitor are indicated. (b)
Densitometric quantitation of the autoradiograms in a.
The Steady-State Amounts of Mitochondrial rRNAs,
mRNAs, and tRNALIj Are Not Significantly Affected by the
MELAS Mutation. To investigate whether the decreased
affinity of mTERF for the target sequence carrying the
MELAS mutation, observed in vitro, resulted in changes in
vivo in the steady-state amounts of the two rRNA species
relative to each other and to the mRNAs, an RNA blot
hybridization analysis was carried out on equal samples of
nucleic acids extracted from the mitochondrial fractions of
43B and 94B cells (Fig. 6b) and 143B cells (data not shown)
9 weeks after transformation. The three cell lines failed to
show any obvious differences in the absolute and relative
amounts of the mitochondrial rRNA, mRNA, and tRNA
species (Fig. 6 a and b). In particular, the relative amount and
the electrophoretic mobility of ND1 mRNA, which is en-
coded immediately downstream of the tRNA LqR gene, were
not different in 43B, 94B (Fig. 6b), and 143B cells (data not
shown). In these experiments, the 16S/12S rRNA and 16S/
mRNA hybridization ratios were similar in the three cell lines
(Table 1).
Fig. 6c shows Southern blot hybridization patterns of
mtDNA from the same samples analyzed in Fig. 6 a and b.
The ratios of amounts of mtRNA to mtDNA and of mRNA
to mtDNA are comparable in the three cell lines (Table 1).
The mtDNAs from 94B and 43B exhibited a fragment length
polymorphism relative to the mtDNA of 143B.
In other experiments, equal samples of the same nucleic
acid preparations analyzed in Fig. 6 a and b were subjected
to RNA transfer hybridization with a tRNAb¶uR probe alone,
or with a mixture of the tRNALeJR probe and a tRNALYS
probe. In both blots, the content of tRNAbLey per unit of
mtDNA was slightly lower (-20%) in 43B cells than in 94B
or 143B cells (Fig. 6d and Table 1). No difference in elec-
trophoretic mobility of the tRNAbeUR in 43B cells, as com-
pared to 94B or 143B cells, could be detected. The tRNALYS
level appeared to be 40-50% higher in 94B and 43B cells than
in 143B cells (Table 1).
DISCUSSION
It seems very likely that the MELAS mutation caused the
disease phenotype in the affected individuals by inhibiting
mitochondrial protein synthesis in muscle and nerve cells,
and probably other cells, and thus by affecting the assembly
of respiratory complexes. Cytochemical evidence that cy-
tochrome c oxidase deficiency is associated with the MELAS
mutation has been recently reported (18). The observation
that the presence in heteroplasmic transformants of levels of
wild-type mtDNA above 6% can protect the cell against the
phenotypic effects of the MELAS mutation has extended to
this mutation the in vitro observations (M.Y., T. Miyatake,
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FIG. 6. Blot hybridization analy-
sis of mitochondrial nucleic acids
from 143B, 94B, and 43B cells. (a and
b) Equal amounts of nucleic acids
were analyzed either directly after
DNase I digestion (a) or after oli-
go(dT)-cellulose chromatography (b)
(T, total; U, unbound fraction; B,
bound fraction), by RNA gel blot hy-
bridization. (c and d) Equivalent sam-
ples of nucleic acids of the three prep-
arations were used for Southern blot
analysis, after EcoRV digestion (c) or
for quantitation of tRNALeuR and
tRNALYS (d).
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Table 1. Quantitation of mitochondrial RNAs
Ratio*
Comparison 143B 94B 43B
RNA/mtDNA Exp.1 0.74 1.0 0.82
Exp.2 1.0 0.86
mRNA/mtDNA Exp.1 1.1 1.0 0.97
Exp.2 1.0 1.1
tRNAeu /mtDNA Blot 1 1.1 1.0 0.78
Blot 2 1.0 1.0 0.79
tRNALYS/mtDNA Blot 2 0.73 1.0 1.1
16S/12St Exp.1 3.4 3.4 3.2
Exp.2 2.7 3.6 3.1
16S/mRNAt Exp.1 1.7 1.7 1.9
Exp.2 1.2 0.9
*Derived from densitometric analysis ofappropriate exposures ofthe
autoradiograms shown in Fig. 6a (Exp. 1), Fig. 6b (Exp. 2), Fig. 6c
and Fig. 6d. Data from comparison oftwo different autoradiograms
are normalized to the 94B value.
tCalculated from densitometric analysis of the autoradiogram for
total RNA shown in Fig. 6a (Exp. 1) or for RNA that did not bind
to oligo(dT)-cellulose, two samples of which are shown in Fig. 6b
(Exp. 2).
tCalculated from densitometric analysis of autoradiograms for total
RNA. The mRNAs analyzed were those for ND5, ND4 and ND4L,
COI, cytochrome b, COII, ATPase 6 and ATPase 8, and COIII.
and G.A., unpublished data) and the in vivo observations (19)
previously made for the MERRF (myoclonic epilepsy and
ragged-red fiber) mutation, making this phenomenon amena-
ble to analysis in an in vitro cell culture system.
As to the mechanism(s) whereby the mutation produces the
protein synthesis defect, the observation that the reduction in
labeling of the various mitochondrial translation products in
the defective transformants was not correlated with their
UUR-encoded leucine content would seem to argue against
an effect of the MELAS mutation on the tRNAbujR function
or stability. On the other hand, one cannot exclude that the
MELAS mutation affects the tRNAI'u synthetase charging
specificity (20), thus producing an instability of the aberrant
polypeptides not necessarily correlated with their UUR-
encoded leucine content.
A defect of transcription termination in vitro at the 16S
rRNA/tRNAuuj boundary in a template carrying the
MELAS mutation was recently reported (21). However, the
present work has provided no evidence to support the
occurrence of such a phenomenon in vivo. The significance
of the slight (=20%o) decrease observed in the steady-state
level of tRNAbtYR in 43B cells relative to that in 143B cells is
uncertain. There were no size alterations of the tRNAbbuR or
of the immediately downstream-encoded ND1 mRNA or of
the 16S rRNA, as detectable by changes in their electropho-
retic mobility.
It is possible that the reduction in affinity ofmTERF for the
mutated target sequence detected in the in vitro assays is
compensated in vivo by hyperexpression of the protein. On
the other hand, the present results do not exclude the
possibility that alterations in the rates of synthesis of the
various RNA species caused by the MELAS mutation could
have been compensated by changes in their stability, nor do
they provide information as to possible mistakes in the
precise processing of the H-strand polycistronic transcripts
or fine alterations in the 3'-terminal sequence of 16S rRNA
which could affect its incorporation into the large ribosomal
subunit or its function. However, the present data at least
argue against the simplest possibility, namely, that the defect
in protein synthesis in the transformants was caused by a
change in the absolute or relative amounts of the different
RNA components, due to defects in the transcription termi-
nation step or to misprocessing of the total H-strand poly-
cistronic transcripts at the level of the tRNAL¶R sequence.
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